Adamas Pharmaceuticals (NASDAQ:ADMS) has published trial data indicating its Gocovri has maintained its treatment effect on motor complications for at least two years.
Shares are up 1.8% after hours.
The Phase 3 open-label EASE LID 2 trial enrolled
223 patients and saw the positive effect in all subgroups, including
those continuing treatment from prior double-blind trials, from placebo
or amantadine immediate release, as well as those with dyskinesia
receiving deep brain stimulation.
“These newly published results suggest that
Gocovri may reduce dyskinesia and OFF as far out as 100 weeks, providing
sustained benefits to patients with levodopa-induced dyskinesia,” says
Dr. Jean Hubble, VP of Medical Affairs for Adamas.
https://seekingalpha.com/news/3540868-adamas-pharma-higher-after-positive-gocovri-trial-data
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.